

## NEOMED LABS strengthens its immunology franchise by acquiring PAIRimmune

07 June 2019 | News

**This acquisition reinforces NLPBI's ability to serve the needs of the health industry from the preclinical stage where this is so critical to develop robust data needed to take informed go/no-go decisions**



The recently merged NEOMED-LABS / Pacific Biomarkers (NLPBI), a leading immunology centric service provider specialized in assay development and clinical laboratory testing for vaccines and soluble large molecules has announced the acquisition of PAIRimmune, Laval, Quebec, a non-GLP preclinical immunology service provider.

With a legacy of more than 20 years in the assay development, immunogenicity and efficacy predictive *in vitro* and *in vivo* models, PAIRimmune's CEO Danielle Poirier and her team have a solid reputation for outstanding science within the community. Since 2015, they work as a CRO with small Biotech, academic groups and the most prestigious vaccine and large molecule Pharma companies.

"As a science-driven organization, nothing makes us happier than seeing talented scientists joining forces with us. This acquisition strengthens our ligand binding and neutralization assays R&D capabilities, and this is a determinant growth engine for each of our biomarkers, bioanalytical and vaccine divisions. PAIRimmune also increases our flow cytometry capacity currently in high demand and places us in a situation to answer positively to requests with either an *in vivo*, *ex-vivo* or immunohistology component. A perfect match!" said Dr Benoit Bouche, NLPBI President and Chief Executive Officer.

This acquisition reinforces NLPBI's ability to serve the needs of the health industry from the preclinical stage where this is so critical to develop robust data needed to take informed go/no-go decisions.

PAIRimmune will pursue its operations under the leadership of Danielle Poirier, Director of Preclinical Services and Matthieu Daugan, Associate Director of Preclinical Services.

PAIRimmune will be rebranded this fall at the same time than NEOMED-LABS and Pacific Biomarkers under the same new corporate identity currently in development.